What Is Mold Illness?
If you're reading this, there's a good chance you've been told your symptoms are stress, anxiety, or "all in your head." You've seen multiple doctors. Your labs come back "normal." But you know something is wrong.
Mold illness — formally called Chronic Inflammatory Response Syndrome (CIRSA multi-system inflammatory illness triggered by biotoxins from water-damaged buildings in genetically susceptible individuals.) — is not an allergy. It is not a fungal infection. It is an innate immune response triggered by biotoxinsToxic substances produced by living organisms (molds, bacteria, actinobacteria) that inhabit water-damaged buildings. They drive a sustained immune response when inhaled, ingested, or absorbed through the skin. produced by organisms found inside water-damaged buildings. And it is identifiable through blood biomarkers that most doctors never think to order.
When genetically susceptible individuals are exposed to these environments, their immune systems cannot properly clear the toxins. The result is a chronic, multi-system inflammatory response that can affect the brain, joints, lungs, gut, and hormonal regulation simultaneously — which is why patients so often get passed from specialist to specialist without answers.
This understanding was developed over 30 years of clinical research by Dr. Ritchie ShoemakerDr. Ritchie Shoemaker. Pioneered the diagnostic and treatment framework for CIRS — a 12-step protocol structured around removing exposure, binding biotoxins, addressing nasal MARCoNS, and restoring regulatory peptides like MSH and VIP. and colleagues, beginning with the observation that patients exposed to water-damaged buildings showed consistent patterns of biomarker abnormalities — patterns that no other disease produces in the same combination. Today, this research forms the foundation of a structured, treatable framework.
CIRS is not caused by mold alone. Water-damaged buildings harbor a complex ecology of microbes (mold, actinobacteria, and other species), microbial fragments, and microbial metabolites — including biotoxins, endotoxins, and inflammagens. Fragments are typically the most inflammatory component. The illness results from the immune response to this mixture — not from fungal infection or allergic reaction. This is why antifungals and antihistamines typically don't resolve symptoms. See the IEP Consensus Statement (PDF) →
Key takeaway: Mold illness (CIRS) is a measurable, multi-system inflammatory response — not an allergy, not in your head — triggered by biotoxins in water-damaged buildings, affecting up to 24% of the population.
How Mold Illness Works
In most people, the immune system identifies biotoxins, tags them for removal, and clears them. In genetically susceptible individuals, this clearance mechanism doesn't function properly. The biotoxins remain in the body, triggering a chronic inflammatory cascade.
The Biotoxin Pathway — originally described by Dr. Shoemaker — maps the sequence of events from initial exposure through chronic illness. Understanding this cascade explains why CIRS affects so many systems and why each stage requires specific intervention.
The Biotoxin Pathway — adapted from the framework described in Dr. Shoemaker's published research
Here is the pathway explained in detail:
Biotoxin Exposure
The individual inhales or contacts the inflammatory mixture inside a water-damaged building — microbial fragments, microbial metabolites (biotoxins, endotoxins, and inflammagens), and intact microbes (mold, actinobacteria, and other species). Fragments are typically the most inflammatory component. It is not just "mold spores" but the full microbial-fragment-and-metabolite ecology that drives the immune response.
Genetic Susceptibility & Immune Recognition Failure
In the approximately 24% of the population carrying HLA-DR susceptibility genes, the adaptive immune system fails to properly recognize and tag these biotoxins for clearance. The toxins persist in the body, continually triggering the innate immune system. This is the genetic "gatekeeper" step — most people clear the toxins without developing illness.
Innate Immune Activation & Cytokine Storm
The innate immune system responds with sustained, escalating inflammation. CytokinesSignaling molecules released by immune cells. Sustained cytokine activation in CIRS drives chronic inflammation across multiple body systems — respiratory, gut, neurological, musculoskeletal. and growth factors — particularly TGF-β1 — rise. MMP-9 elevates, disrupting tissue within blood vessel walls and driving widespread inflammation. This is not a brief inflammatory response that resolves; it is a self-perpetuating cycle as long as the biotoxin remains.
Regulatory Collapse
The sustained inflammatory pressure drives down key regulatory hormones and peptides. MSH drops (in ~94% of CIRS patients), disrupting sleep, pain, mood, gut function, and immune regulation. VIP drops, affecting vascular and pulmonary function. ADH may drop, causing excessive thirst and urination. VEGF is disrupted, affecting capillary perfusion and oxygen delivery to tissues.
Multi-System Inflammation
The cascade produces symptoms across multiple organ systems simultaneously — neurological, musculoskeletal, respiratory, gastrointestinal, and cognitive. This multi-system presentation is a hallmark of CIRS and the reason it is so frequently misdiagnosed as multiple separate conditions.
Because CIRS affects many systems at once, patients are often sent to multiple specialists — neurologists, rheumatologists, pulmonologists, psychiatrists — who each treat their organ system in isolation. Without the unifying biotoxin framework, the underlying cause goes unidentified, and symptoms persist or worsen.
Key takeaway: In genetically susceptible individuals, biotoxins aren't cleared properly — triggering a cascade from immune activation to regulatory collapse that explains why symptoms hit every system at once.
Recognizing the Symptoms
CIRS does not produce one or two telltale symptoms. It produces clusters — groups of symptoms that span multiple organ systems simultaneously. This multi-system presentation is one of the defining characteristics of biotoxin illness, and it is the reason patients are so often misdiagnosed or dismissed.
Dr. Shoemaker's clinical research, spanning over 10,000 patients, identified 13 distinct symptom clusters that CIRS patients typically present with. A cluster is positive when one or more of its symptoms applies — and reporting symptoms in 8 or more of the 13 clusters increases the likelihood of CIRS substantially. No single cluster confirms the diagnosis — it is the pattern across multiple clusters, combined with biomarker evidence and exposure history, that points to CIRS. Read the CIRS diagnostic protocol (PDF) →
The cluster framework is significant because it moves beyond vague symptom lists toward a structured, reproducible pattern. When a patient presents with symptoms spanning 8+ of 13 defined clusters — and those symptoms began or worsened after water-damaged building exposure — the probability of CIRS increases substantially, especially when paired with objective biomarker abnormalities.
The 13 Symptom Clusters
Tap a card to expand its symptoms. Tap the circle on the right to tick clusters that apply. Eight or more ticked = elevated likelihood of CIRS.
What the Research Shows
Several of these clusters have been studied in significant depth. Understanding the mechanisms behind the symptoms helps explain why conventional treatments often miss the mark.
Cognitive symptoms & brain volume
Cognitive symptoms — memory loss, word-finding difficulty, decreased concentration, disorientation — are not a single CIRS cluster. They appear across multiple clusters in the published grouping above, and they have been studied in particular depth because they are among the most disabling and most measurable symptoms.
Using NeuroQuant MRI volumetrics, research has documented cortical grey matter injury, grey matter nuclear atrophy, and ventricular enlargement following water-damaged building exposure. These findings are objective evidence that biotoxin exposure can cause physical changes in brain tissue — not subjective complaints.
A subsequent study found that intranasal VIP treatment safely restored volume to multiple grey matter nuclei in CIRS patients — suggesting some of these changes are reversible. A significant finding for patients who have been told their cognitive decline is permanent or psychological.
Shoemaker RC, Katz D, Ackerley M, Rapaport S, McMahon S, Berndtson K, Ryan JC (2017). Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS. Internal Medicine Review. Read the paper →
Chronic Fatigue & Hypometabolism
The fatigue experienced by CIRS patients has a molecular basis. Transcriptomic analysis has revealed suppression of ribosomal and mitochondrial gene expression — a state researchers term "molecular hypometabolism." In plain terms: the cellular machinery that produces energy is measurably suppressed.
This finding is significant because it validates what patients report — that their fatigue is not laziness, depression, or deconditioning, but a real physiological state. The research also shows this hypometabolic state reverses during treatment, with VIP therapy correcting overshoot through insulin signaling pathways.
Ryan JC, Shoemaker RC (2018). Chronic Fatigue: Reversible Hypometabolism Shown by Transcriptomics.
Pain Syndromes
Joint and muscle pain in CIRS are not caused by mechanical injury or autoimmune attack. Research has identified that the same inflammatory mediators driving the innate immune response to biotoxin exposure — particularly elevated MMP-9 and TGF-β1 — are directly involved in the musculoskeletal pain that affects an estimated 85%+ of CIRS patients.
This explains why pain persists despite normal rheumatological workups, negative imaging, and failed treatment with anti-inflammatory medications. The pain is real, measurable through biomarkers, and driven by the underlying inflammatory process — not by tissue damage or degeneration.
Shoemaker RC, Ryan JC (2018). Inflammatory Responses Acquired Following Environmental Exposures Are Involved in Pain Syndromes.
The MSH Connection
Many CIRS symptom clusters trace back to a single upstream problem: low MSH (melanocyte-stimulating hormone). Research suggests MSH is low in approximately 94% of CIRS patients. This matters because MSH is not just one hormone — it is a master regulatory peptide that controls:
Sleep — MSH regulates sleep-wake cycles. Low MSH disrupts restorative sleep, compounding fatigue.
Pain perception — MSH modulates pain pathways. Low MSH amplifies pain signals.
Gut function — MSH regulates gut motility and mucosal immunity. Low MSH contributes to GI symptoms.
Mood — MSH influences neurotransmitter balance. Low MSH contributes to depression and irritability.
Immune regulation — MSH is anti-inflammatory. Without it, the inflammatory cascade continues unchecked.
Nasal defense — Low MSH creates conditions that allow MARCoNSMultiple Antibiotic Resistant Coagulase Negative Staphylococci. A biofilm-forming bacterial colonization in deep nasal passages, common when MSH is low. Must be cleared before VIP therapy can succeed. (antibiotic-resistant staph) to colonize deep nasal passages.
This single biomarker abnormality helps explain why CIRS patients experience symptoms across so many apparently unrelated systems. They are not unrelated — they share a common regulatory failure.
Neurodegeneration Risk
Recent research has identified a transcriptomic fingerprint — including genes TUBA4A, TUBB1, and clusterin (CLU) — found in both symptomatic Parkinson's disease patients and younger CIRS patients. This finding, termed "Triple Positives," suggests that chronic water-damaged building exposure may contribute to neurodegenerative pathways earlier than previously recognized.
While this research is still developing, it underscores the importance of early identification and treatment of CIRS — the inflammatory processes driving current symptoms may also carry long-term neurological implications.
Shoemaker RC, Ryan Z, Heyman A, McMahon S, Lark D (2024). A Transcriptomic Fingerprint for Parkinson's Disease Found in CIRS Patients.
Individual symptoms can occur in many conditions — but no other published disease produces the multi-cluster pattern described above following water-damaged building exposure. Eight or more clusters is a meaningful clinical signal. That said, the 13-cluster framework is a screening tool, not a diagnosis. A definitive evaluation requires biomarker testing, exposure history, and clinical assessment by a CIRS-literate provider. This guide is educational — not diagnostic.
Key takeaway: CIRS produces symptoms across 13 defined clusters. The multi-system pattern — not any single symptom — is what distinguishes it. Most patients report 8+ clusters. A qualified provider can help you evaluate this.
Wondering if your symptoms could be mold-related?
MoldCo — built by former patients who navigated mold illness themselves — offers a Starter Health Panel that tests TGF-β1, MMP-9, and MSH at any LabCorp location. Three biomarkers. One blood draw. Real data to start with.
Order Starter Panel — $56MoldCo's testing is guided by published research. Results should be reviewed with a qualified healthcare provider. The Mold Report's editorial coverage is independent of MoldCo.
The Biomarkers
One of the most significant advances in mold illness research is the identification of measurable blood biomarkers that correlate with CIRS. These markers provide objective data about what is happening in the immune system — moving beyond symptom checklists to lab-verified patterns.
| Biomarker | What It Is | In CIRS | What It Indicates |
|---|---|---|---|
| TGF-β1Transforming Growth Factor Beta-1. A cytokine and growth factor — not a hormone — involved in tissue remodeling and immune regulation. Elevated in CIRS. | Cytokine/growth factor involved in tissue remodeling and immune regulation | Elevated | Active inflammation and immune dysregulation |
| MMP-9Matrix Metalloproteinase-9. An enzyme that breaks down tissue. Elevated levels indicate vascular inflammation and are a key CIRS biomarker. | Matrix metalloproteinase — an enzyme involved in tissue breakdown | Elevated | Vascular tissue disruption; widespread inflammation |
| MSHMelanocyte-Stimulating Hormone. A master regulatory peptide controlling sleep, pain, mood, gut function, and immune regulation. Low in ~94% of CIRS patients. | Melanocyte-stimulating hormone — regulates sleep, pain, mood, gut, and immune function | Low | Central regulatory failure (low in ~94% of patients) |
The CIRS immune fingerprint — the pattern of simultaneous elevation and suppression across key biomarkers
Published research has identified that the simultaneous combination of elevated MMP-9 and TGF-β1 with low MSH is an immune fingerprint specific to CIRS — no other disease in the published literature is known to produce this exact dysregulation across all three markers at once. This is what makes pattern-based biomarker testing so powerful: it provides an objective signal rather than relying on subjective symptom reporting alone.
Note: TGF-β1 is a cytokine and growth factor — not a hormone. This distinction matters because it reflects immune activation and tissue remodeling, not endocrine dysfunction. Accurate terminology helps patients and providers communicate clearly.
Beyond the Core Six: The Full Biomarker Panel
The six markers above are the most commonly referenced starting points. However, the published diagnostic framework identifies a much broader set of laboratory abnormalities. Research across thousands of CIRS patients has documented abnormalities in dozens of markers spanning innate immunity, adaptive immunity, hormonal regulation, coagulation, and more recently, genomic transcriptomics.
Additional markers that may be evaluated in a comprehensive CIRS workup include:
The consensus diagnostic statement (Shoemaker et al., 2018) describes a comprehensive evaluation protocol that integrates these markers with symptom clusters, exposure history, and increasingly, transcriptomic data that can identify specific gene expression patterns associated with CIRS at the molecular level. The breadth of the published marker panel reflects the multi-system nature of the disease — CIRS is not a single-marker condition.
Key takeaway: Blood biomarkers like TGF-β1, MMP-9, and MSH create a measurable immune fingerprint. The pattern across multiple markers — not any single value — is what gives providers objective data to work with.
Getting Tested
This is where it gets actionable. If you suspect mold illness, the first concrete step is blood biomarker testing. These tests are standard laboratory panels run at facilities like LabCorp — there is nothing experimental about the individual tests themselves. The difference is knowing which markers to look at and how to interpret the patterns.
A starting panel $56–$799 at MoldCo typically includes TGF-β1, MMP-9, and MSH. These three markers, together, can provide initial insight into whether an inflammatory pattern consistent with biotoxin exposure is present. More comprehensive panels may add C4a, VIP, VEGF, and other markers. Beyond blood work, home environmental testing (HERTSMI-2 / ERMIEnvironmental Relative Moldiness Index. A dust test quantifying 36 mold species — both water-damage indicators and common background molds — to assess a home's overall mold burden.) and HLA genetic testing can complete the picture — telling you not just whether you're inflamed, but whether your environment is driving it and whether your genetics make you susceptible.
Urine mycotoxinA toxic compound produced by certain molds. One of several biotoxin classes that drive CIRS inflammation. Note: urine mycotoxin testing is not clinically validated for CIRS diagnosis — blood biomarker testing is the validated approach. testing is commercially available but has significant limitations. Published research has noted concerns including the lack of validated case definitions, absence of proper control groups, and potential confounding from dietary mycotoxin exposure. Blood biomarker testing provides more clinically validated data for evaluating mold-related illness.
What to expect: Blood biomarker testing is a standard blood draw at a laboratory. Results typically take 5–10 business days. The markers themselves are well-established laboratory tests. The interpretation of results in the context of mold-related illness should ideally involve a provider experienced with this specific biomarker pattern — because the pattern matters more than any single value.
Key takeaway: Start with blood biomarker testing (TGF-β1, MMP-9, MSH) at a standard lab. The tests are routine — it's the interpretation in context that requires a knowledgeable provider.
Ready to test your biomarkers?
MoldCo's Starter Health Panel ($56) tests TGF-β1, MMP-9, and MSH at any LabCorp location. No doctor's visit required to order. Results are delivered to your online dashboard, where MoldCo's providers can help you interpret what the data means.
Order the Starter Health PanelTesting provides data, not diagnosis. MoldCo recommends reviewing results with a qualified healthcare provider experienced in mold-related illness.
The Treatment Framework
This is hard. You're not alone. The work is worth it.
If you're reading this in the middle of the protocol, here's what I want you to know.
It's hard. Genuinely, structurally hard. The illness is brutal. The protocol is demanding. There are weeks where you'll feel worse before you feel better — and that's not a sign you're doing it wrong. Removing exposure and binding biotoxins is supposed to disturb things on the way to clearing them.
I'm one of the founders of MoldCo. We're former patients ourselves — we built the clinic because the care we needed when we were sick didn't exist. What we see across our own cohort matches the research: bad weeks, plateaus, then measurable improvement. We designed the care around what would have helped us — unlimited provider access for the hard weeks, dashboard tracking so the slow signal is visible, and a structure that keeps the protocol's order intact. It's the framework, delivered by people who lived it.
You're not alone. Tens of thousands of people have moved through this framework over the past 25 years. Most had moments where they wanted to stop. Most kept going.
Improvement isn't a straight line. Better days come back before they stay. Symptoms shift before they fade. Biomarkers move before you feel it. The pattern is real — bodies respond to the protocol, on their own timeline.
Take it one phase at a time. Stay in close contact with your provider. Track what changes, even when it feels like nothing changed. Some weeks the only win will be that you didn't quit.
You're not crazy, you're not weak, and you're not making it up. CIRS is real, the framework is evidence-based, and you can keep going.
— Julien
Treatment for mold toxicity follows the Shoemaker Protocol — a sequential, step-by-step framework developed through Dr. Shoemaker's clinical research over decades. The protocol has been used in 30,000+ patient cases across Shoemaker and the broader network of Shoemaker-certified practitioners.
To be clear: the 30,000+ figure reflects use of the Shoemaker Protocol across the certified-practitioner network over decades. It is not MoldCo's own patient count. MoldCo is a virtual clinic delivering the protocol; our patient base is smaller and growing.
The key insight from treating thousands of patients: when the first three steps are completed properly — removing exposure, binding toxins, and clearing MARCoNS — inflammatory markers typically begin normalizing on their own. Rather than adding a separate marker-correction phase, MoldCo's approach moves directly to VIP therapy, the step with the most profound documented effects on brain volume, regulatory function, and long-term outcomes.
The four-step Shoemaker Protocol — based on published research, used in 30,000+ patient cases across Shoemaker and Shoemaker-certified practitioners
Remove Exposure
The single most important step. If the biotoxin source is not eliminated from the patient's environment, no treatment can produce lasting improvement. This may involve professional remediation, environmental testing (HERTSMI-2), or relocation from a water-damaged space. MoldCo offers home dust testing to help patients assess their environment.
Binding Agents
Colesevelam (Welchol) or cholestyramine (CSM) may be used as binding agentsAgents (typically cholestyramine or colesevelam) taken with meals to bind biotoxins in the gut, preventing re-absorption and allowing the body to eliminate them. Step 2 of the Shoemaker Protocol. to help remove biotoxins from the body. These agents work in the gut to bind toxins and facilitate their elimination rather than allowing recirculation. MoldCo's providers guide patients through this phase with ongoing support and monitoring $107–$313 / month.
Address MARCoNS
MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) are antibiotic-resistant bacteria that may colonize the deep nasal passages when MSH is low. If a nasal culture comes back positive, addressing this colonization is important before the body can begin recovering its regulatory function.
VIP (Vasoactive Intestinal Peptide)
The final and most impactful stage. VIP is a neuropeptide with broad regulatory functions. Research has demonstrated that intranasal VIP may safely help restore grey matter volume, reduce inflammatory markers, normalize clotting abnormalities, and correct the molecular hypometabolism driving chronic fatigue. Across the 30,000+ patient cases documented by Shoemaker and Shoemaker-certified practitioners, completing the first three steps properly is what allows patients to move directly to VIP therapy — rather than spending months correcting individual markers one at a time.
This four-step framework reflects Dr. Shoemaker's published research and the 30,000+ patient cases documented by Shoemaker and Shoemaker-certified practitioners. MoldCo's providers are trained in this protocol and personalize individual treatment plans. Treatment outcomes vary, and all care should be managed by a qualified healthcare provider.
Key takeaway: Treatment follows a sequential framework: remove exposure, bind toxins, address MARCoNS, then VIP therapy. The order matters — each step enables the next. Work with a provider experienced in this approach.
What the research shows about improvement
If you're in the middle of the protocol, this section is for you. CIRS is brutal and the framework is demanding. Here is what the published research documents about patient improvement when the protocol is completed sequentially.
Intranasal VIP treatment (greater than 12 weeks, 6+ doses/day) has been documented to safely correct multinuclear grey matter atrophy in CIRS patients, while reducing MMP-9, TGF-β1, and C4a, raising VEGF, and normalizing clotting abnormalities.
Shoemaker RC, Katz D, Ackerley M, Rapaport S, McMahon S, Berndtson K, Ryan JC (2017). "Intranasal VIP Safely Restores Volume to Multiple Grey Matter Nuclei in Patients with CIRS." See full citation →
The molecular hypometabolism (suppressed ribosomal and mitochondrial gene expression) that drives chronic fatigue in CIRS patients has been documented to reverse during treatment, with VIP therapy correcting overshoot via insulin signaling mechanisms.
Ryan JC, Shoemaker RC (2018). "Chronic Fatigue: A condition of reversible hypometabolism in many cases as shown by RNA-Seq." See full citation →
A 2024 peer-reviewed literature review of 13 CIRS treatment articles identified the Shoemaker Protocol as the only treatment with documented clinical efficacy for CIRS, with efficacy demonstrated in 11 of the 13 articles reviewed.
Dooley M, Vukelic A, Jim L (2024). "Chronic Inflammatory Response Syndrome: A Review of the Evidence of Clinical Efficacy of Treatment." See full citation →
Three more peer-reviewed papers and a 25-year retrospective are catalogued on our research page, with the source link for each so you can verify them yourself.
None of this predicts an individual outcome. Bodies don't all heal on the same timeline. But the research is real, the framework has documented results across thousands of cases, and the evidence shows improvement is what the protocol is designed to produce.
of MoldCo patients see symptom reduction in the first 30 days
Beyond the published research above, MoldCo tracks symptom-reduction outcomes in its own patient cohort. The first 30 days of treatment focus on removing exposure, beginning binder therapy, and stabilizing inflammatory markers — the steps with the fastest measurable effect on day-to-day symptoms.
Source: MoldCo internal patient outcome data. Self-reported symptom assessments. Individual results vary. The Mold Report's editorial coverage is operated by MoldCo's head of growth — see disclosures.
Ready to start treatment with providers who specialize in this?
MoldCo is America's leading provider-led virtual clinic for mold toxicity — founded by former patients who joined forces with Dr. Shoemaker and Dr. Scott McMahon to build the care they wished existed. Lab testing, home testing, genetic testing, and provider-guided treatment in one platform, with an online dashboard, education resources, and unlimited access to your care team.
Explore MoldCo CareMoldCo does not diagnose CIRS. Its providers deliver care guided by published research. Individual results vary. This is not medical advice.
Your Home & Environment
Because the first step of treatment is removing exposure, understanding your home environment is critical. Mold growth can begin within 24–48 hours of water intrusion — and it can develop in hidden spaces like wall cavities, HVAC systems, and under flooring.
HERTSMI-2Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens. An environmental test measuring 5 mold species associated with water-damaged building illness. Score below 11 is generally considered safe. (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens, 2nd version) is an environmental testing method that measures five specific mold species associated with water-damaged building illness. A HERTSMI-2 score below 11 is generally considered safe for CIRS patients.
Identify Water Intrusion
Check for current or past water damage: roof leaks, plumbing failures, condensation issues, basement flooding, and HVAC problems. Even past water damage that appears "dried out" can harbor active growth in hidden spaces.
Important: Removing exposure is the goal — but you do not have to wait until you have left the building to begin treatment. Patients can start binders (Step 2 of the protocol) while still working to leave the water-damaged building. Your body still benefits from clearing biotoxins regardless of whether the source is fully resolved.
Test Your Environment
ERMI (Environmental Relative Moldiness Index) and HERTSMI-2 testing use dust samples to identify specific mold species. Unlike air testing, dust sampling captures longer-term exposure data and the specific species most associated with illness.
Professional Remediation
If testing confirms elevated levels, professional remediation by an experienced company is recommended typically $5,000–$25,000. Proper remediation addresses the moisture source (not just the visible mold), removes contaminated materials, and verifies clearance through post-remediation testing.
Become a home detective
Use your senses. A musty, earthy smell is the most reliable sign of active mold. Follow that clue with a visual hunt for water damage in these common hotspots.
Kitchens
- Under the sink for drips
- Behind the refrigerator
- Inside the pantry
Bedrooms
- Condensation on windows, especially in corners
- Behind furniture against exterior walls
Bathrooms
- Shower tile grout
- Under the sink
- Around the base of the toilet
- Poor ventilation (is there an exhaust fan?)
Laundry rooms
- Washing machine hoses for leaks
- Dryer vents for blockages
Basements & crawl spaces
- The most common source of hidden mold
- Watch for ground moisture, lack of light, musty air
HVAC systems
- Musty smell when the system turns on
- Drain pan and visible ductwork
- Coils, drip pans, uninsulated ducts
- Filters overdue for replacement
Wall cavities & ceilings
- Water stains or discoloration
- Bubbling or peeling paint
The right test for a real answer
For a data-driven assessment, use the HERTSMI-2 $199 at MoldCo — a dust test that analyzes the DNA of the 5 most problematic mold species and gives you a single score. For a broader picture, the ERMI measures 36 species, including both water-damage indicators and common background molds.
Good news for your current living space. If you're still symptomatic, exposure may have occurred in a previous home, school, or workplace.
Warrants further investigation by a professional inspector to pinpoint the source. Aggressive cleaning and air purification are essential.
Strong evidence that your home is a source of toxic exposure. Top priority: a plan for professional remediation or relocation.
Order a HERTSMI-2 home test
A dust-DNA test for the 5 most problematic mold species. Ships to your home; no doctor visit required. Results delivered in your dashboard.
Order HERTSMI-2 — $199Not all experts are created equal
The company that tests should not be the company that remediates. Hire two separate experts: an independent Indoor Environmental Professional (IEP) to inspect, and a certified remediation company to do the cleanup. This prevents conflicts of interest and ensures the job is done right.
What to look for
- Independent. Inspects and tests only — does not perform remediation. Their job is to be your unbiased scientific advocate.
- CIRS-literate. Familiar with the Shoemaker Protocol and HERTSMI-2 testing for chronically ill patients. If they dismiss these concepts, they're not the right fit.
- Right tools. Moisture meters, thermal imaging cameras (to find hidden leaks), and DNA-based dust tests (ERMI / HERTSMI-2) — not just unreliable air samples.
- Right certifications. Active credentials through ACAC, NORMI, or IICRC. Look for at least one.
What to look for
- Follows IICRC S520. The non-negotiable industry gold standard for safe, effective remediation.
- Proper containment. Plastic sheeting and negative-air-pressure scrubbers to prevent cross-contaminating the rest of your home.
- Agrees to third-party clearance testing. A confident remediator welcomes an independent IEP back to verify success.
Find a vetted IEP through IAQA.org (Indoor Air Quality Association) or IICRC.org (Institute of Inspection, Cleaning and Restoration Certification). Conduct due diligence with your local Department of Consumer Affairs and Better Business Bureau before signing.
For individuals with suspected CIRS, DIY mold removal is not recommended. Disturbing mold colonies can release large quantities of spores and biotoxins. Professional remediation with proper containment, negative air pressure, and personal protection is the safer path.
Recommended: Mold Controlled by John C. Banta
The definitive guide to mold inspection and remediation. Written by one of the most experienced environmental consultants in the field. Essential reading if you're dealing with a water-damaged building.
Get the book →Key takeaway: Removing exposure is step one. Test your environment with HERTSMI-2/ERMI, hire professionals for remediation, and use John Banta's guide as your reference. Do not attempt DIY mold removal.
The Research
The understanding of CIRS and its treatment is grounded in published, peer-reviewed research spanning over two decades. Below are key papers that form the scientific foundation of the field.
Watch: Dr. Shoemaker & Dr. McMahon on CIRS
Dr. Ritchie Shoemaker and Dr. Scott McMahon discuss Chronic Inflammatory Response Syndrome, the research behind it, and the clinical approach to diagnosis and treatment.
Establishes a formal consensus diagnostic protocol for CIRS requiring abnormalities in innate immune responses, including reduced MSH and VIP, elevated C4a, MMP-9, and TGF-β1, supported by transcriptomic confirmation.
Combined transcriptomic testing and NeuroQuant brain volumetrics identify specific causation of cognitive impairment from water-damaged building exposure, including cortical grey matter injury and ventricular enlargement.
Identifies a unique transcriptomic fingerprint including TUBA4A, TUBB1, and clusterin found in both symptomatic Parkinson's patients and younger CIRS patients, suggesting water-damaged building exposure may contribute to neurodegeneration.
HIF 1A pathway overexpression drives proliferative physiology and pulmonary artery hypertension in CIRS patients. VIP therapy reduces HIF 1A by resolving aberrant mitochondrial transcriptomics.
Intranasal VIP treatment safely corrected multinuclear grey matter atrophy in CIRS patients while reducing MMP-9, TGF-β1, C4a, raising VEGF, and normalizing clotting abnormalities.
CIRS patients show suppression of ribosomal and mitochondrial gene expression (molecular hypometabolism) that reverses during treatment, with VIP therapy correcting overshoot via insulin signaling mechanisms.
Demonstrates that urinary mycotoxin testing lacks validated case definitions, proper control groups, and case-control studies. Dietary mycotoxins confound results, and the CDC has repudiated this practice.
25-year retrospective describing the evolution from identifying water-damaged building illness through biotoxin paradigm, biomarker development, and transcriptomics to a point where CIRS can be characterized as addressable through gene-level correction.
Frequently Asked Questions
Questions to Bring to Your Provider
Print or screenshot this list. These are informed questions that can help guide a productive conversation with your doctor.
- "Can you order TGF-β1, MMP-9, and MSH blood panels?" — These are standard LabCorp tests. Most doctors can order them even if they're unfamiliar with CIRS.
- "Have you evaluated me for biotoxin-related illness or CIRS?" — This introduces the framework without self-diagnosing. Many providers haven't encountered it.
- "Could my symptoms be connected to water damage in my home or workplace?" — Establishes exposure history, which is a critical diagnostic factor.
- "Would you be open to reviewing my results with a provider who specializes in mold-related illness?" — Opens the door to specialist referral without confrontation.
- "Are there environmental tests I should consider for my home?" — Introduces HERTSMI-2/ERMI testing as a next step for investigating exposure.
- "What do you know about the Shoemaker Protocol for biotoxin illness?" — Gauges whether your provider has relevant training and opens a research-grounded conversation.
Your Next Steps
If you've read this far, you have a real foundation in the science of mold illness — more than most doctors will ever learn about this condition. Here is the path from knowledge to action:
Looking for a different provider? Browse our directory of 28 Shoemaker Protocol-certified practitioners across the U.S. and internationally — sourced from Surviving Mold's official list.
MoldCo is America's leading provider-led virtual clinic for mold toxicity — founded by former patients, guided by published research. MoldCo does not diagnose CIRS. Individual results vary. Always consult a qualified healthcare provider for medical decisions. The Mold Report's editorial coverage is independent of MoldCo.